title: The pharmacokinetics of recombinant human erythropoietin after intravenous and subcutaneous administration to healthy subjects.
abstract: 1. The pharmacokinetics of recombinant erythropoietin, r-Epo, were evaluated after intravenous and subcutaneous administration of 50 u kg-1 to six healthy male volunteers. 2. The calculated mean values (+/- s.d.) for volume of distribution at steady state and clearance after an i.v. dose were 76 (+/- 33) ml kg-1 and 12 (+/- 3) ml h-1 kg-1, respectively. 3. Serum concentrations of r-Epo peaked at 13 (+/- 6) h after the s.c. dose and the bioavailability over 72 h was 36 (+/- 23)%. The mean residence time and half-life of erythropoietin were 6.2 (+/- 1.0) and 4.5 (+/- 0.9) h respectively after i.v. and 46 (+/- 18) and 25 (+/- 12) h after s.c. administration. 4. The results demonstrate the possibility of changing the profile of the concentration-time curve by changing the mode of administration of r-Epo, with implications for the time-course of clinical response.
authors.affiliation: National Board of Health and Welfare, Department of Drugs, Uppsala, Sweden.
authors.forename: T
authors.initials: T
authors.lastname: Salmonson
authors.forename: B G
authors.initials: BG
authors.lastname: Danielson
authors.forename: B
authors.initials: B
authors.lastname: Wikström
mesh_terms: D000328:Adult; D001682:Biological Availability; D004921:Erythropoietin / Q000008:administration & dosage / Q000493:pharmacokinetics*; D006207:Half-Life; D006801:Humans; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D008297:Male; D011863:Radioimmunoassay; D011994:Recombinant Proteins / Q000493:pharmacokinetics
chemical_list: D011994:Recombinant Proteins; D004921:Erythropoietin